EFFECTIVENESS OF NATEGLINIDE ON IN WTRO 79 insulin secretion and enhances glucose clearance in Type 2 diabetes, Diabetes, 49, Al13. [13] Hollander, P. A., Schwartz, S. L., Gatlin, M. R., Haas, S., Zheng, H., Foley J. E. and Dunning, B. E. (2000). Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post- meal glucose excursions with less total insulin exposure, Diabetes, 49, Al11. [14] Lacy, P. E. and Kostianovsky, M. (1967). Method for the isolation of intact islets of Langerhans from the rat pancreas, Diabetes, 16, 35-39. [15] Cook, N. D. (1996). Scintillation proximity assay: a versatile high-throughput screening technology, Drug Disc. Trends, 1, 287- 294. [16] Henquin, J. C. (1980). Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets, Diabetologia, 18, 151-160. [17] Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R. and Boettcher, B. R. (2000). Pancreatic B-cell KArT channel activity and receptor binding studies with nateglinide: a comparison with sulphonylureas and repaglinide, J. Pharmacol. Exp. Ther., 293(2), 444-452. [18] Leclercq-Meyer, V., Ladriere, L., Fuhlerdorff, J. and Malaisse W. J. (1997). Stimulation of insulin and somatostatin release by two meglitinide analogs, Endocrine, 7(3), 311-317. [19] Tsukuda, K., Sakurada, M., Niki, I., Oka, Y. and Kikuchi M. (1998). Insulin secretion from isolated rat islets in- duced by the novel hypoglycemic agent A-4166, a deri- vative of D-phenylalanine, Horm. Metab. Res., 30, 42-49. [20] Dunning, B. E. and Paladini, S. (1999). Mimicking cephalic insulin release with the rapid onset/short duration insulinotropic agent, nateglinide, reduces prandial glucose excursions without increasing total insulin exposure in IGT monkeys, Diabetes, 48(1), A282. [21] Dunning, B. E. and Gutierrez, C. (1999). Pharmacody- namics of nateglinide and repaglinide in cynomolgus monkeys, Diabetes, 48(1), A104. [22] DeSouza, C. J., Gagen, K., Chen, W. and Dragonas, N., Superior glycemic control with early insulin release v/s total insulin release in thpe-2 diabetic rodent models, Diabetes, 48(1), A270. [23] Seto, Y., Fujita, H., Dan, K., Fujita, T. and Kato, R. (1995). Stimulating activity of A-4166 on insulin release in in situ hamster pancreatic perfusion, Pharmacology, 51, 245-253. [24] Hu, S. and Wang, S. (1998). Effect of antidiabetic agent, netaglinide, on KATP channel in/3-cells: comparison to glyburide and repaglinide, Diabetologia, 41 Suppl., A139. [25] Fujitani, S., Okazaki, K. and Yada, T. (1997). The ability of a new hypoglycemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic B-cells under metabolic inhibition, Br. J. Pharmacol., 120, 1191-1198. INTERNATIONAL JOURNAL OF EXPERIMENTAL DIABETES RESEARCH